The Chinese government encourages oversea investments in healthcare, and a company like Jangho wouldn't put out an indicative proposal if they didn't have strong confidence in obtaining finance, as it would be "loosing face" - a big deal for Chinese people. Risks for the deal are probably most likely FIRB approval and HLS board view.
Not the best valuation but the equity market could get pretty ugly in the next 2 years so at this price point HLS should give it some serious thought.
From what I've heard Vision Eye is doing very well since the Jangho acquisitions as it is still Australian managed but reaps synergies from Jangho's China ophthalmic chains and customer base.
Ann: Non-binding indicative proposal for acquisition of Healius, page-29
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add HLS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.35 |
Change
0.035(2.66%) |
Mkt cap ! $1.212B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.36 | $1.33 | $1.778M | 1.321M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6637 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.35 | 6178 | 2 |
View Market Depth
| Last trade - 16.10pm 22/11/2024 (20 minute delay) ? |
| HLS (ASX) Chart |
